November 09, 2006

CYP2D6 Gene May Contribute to Persistent Negative Symptoms

The polymorphic cytochrome P450 2D6 (CYP2D6) gene creates enzymes which affect the metabolism of some antidepressants, antipsychotics, beta-blockers, and chemotherapy medications. Although variations in this gene have been implicated in exacerbating extrapyramidal symptoms (EPS) in patients on long-term treatment with antipsychotic medications, the evidence to date has been inconclusive.

While further studying the gene's possible impact on EPS, scientists in Slovenia evaluated a small group of outpatients with the diagnosis of schizophrenia or schizoaffective disorder, stable, and on long-term maintenance therapy. Although they did not find an impact of the CYP2D6 gene on EPS, they did find a possible correlation between that gene and persistent negative symptoms.

Link to original article in the Journal of Psychopharmacology: "The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment"

Additional Reading about the polymorphic cytochrome P450 2D6 (CYP2D6) gene:


Hi Jeanne, I blog occasionally about CYP2D6 testing and related medications over at DNA Direct Talk. Currently I'm tracking on the CYP2D6 gene because my company recently began offering CYP2D6 testing for consumers as well as physicians. (DNA Direct's company site)

Posted by: Lisa Lee at November 21, 2006 01:10 PM

Thank you for the information. I truly do believe genetic testing will someday be very useful once we fully know what to do with the information obtained from it.

Posted by: Jeanie at November 24, 2006 12:34 PM

Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required